Hepatocellular carcinoma: Is current therapy really altering outcome?

Philip Johnson

Research output: Contribution to journalArticle

97 Citations (Scopus)


Progress in the management of hepatocellular carcinoma (HCC) has been slow and has limited impact on outcome. Most patients with HCC have two diseases--chronic liver disease and HCC--and complex interactions between the two have major implications for diagnosis and prognosis as well as the management of HCC. The disease is most prevalent in those areas of the world where the infrastructure for clinical trials is least developed. Also, the aetiology of the disease varies around the world and it is still not known whether HCCs of different aetiologies have different prognoses. Current treatment is making an impact on the management of HCC but further progress awaits not only the development of more effective treatments but also the development of adequate methodologies to assess the impact of these treatments.
Original languageEnglish
Pages (from-to)459-462
Number of pages4
Issue number4
Publication statusPublished - 1 Oct 2002


Dive into the research topics of 'Hepatocellular carcinoma: Is current therapy really altering outcome?'. Together they form a unique fingerprint.

Cite this